If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
The company is a Turkish startup with the main focus on novel and high-level pharmaceutically active ingredients. They develop a protein inhibitor which is a target-based small molecule, druggable regulatory factor. It inhibits the transcription of genes regulated by a homeobox meis protein by modulating the activity of this protein. They are looking for technical cooperation to develop kits to be used in the determination of meis+ (producing meis proteins on their cells) patients.
The company is a Turkish deep-tech startup established in 2018 by a genetics and bioengineering faculty member with the main focus on novel and high-level pharmaceutically active ingredients. Its team consists of molecular biologists, medical doctors and pharmacologists from academy and industry who are highly experienced in protein chemistry and drug development with a successful history of basic research and molecule design backed with many research grants and awards.
The company develops meis inhibitor which is a target-based small molecule, druggable regulatory factor. Meis inhibitor inhibits the transcription of genes regulated by meis proteins by modulating the activity of meis protein.
Meis proteins play a critical role in cell metabolism and are proven to be highly associated with diseases such as cancer, cardiovascular diseases, diabetes and obesity. The benefit presents to the targeted drug discovery researchers is providing insight into the biologic mechanisms of the non-communicable diseases. The molecule also has the potential of being used as a drug in its treatment.
Meis inhibitors provide targeted therapy to patients by distinguishing between meis+ cancer types and disease-causing oncogene. Using meis inhibitors on meis+ phenotype patients increases the success of personalized treatment.
There are no diagnostic tools available in the market that can determine meis+ patients therefore the company is looking for partnerships to develop meis+ patient diagnosis kits.
The company is looking for a technical cooperation agreement to develop kits to be used in the determination of meis+ patients.
The company is looking for a partner experienced in developing and manufacturing diagnosis kits to detect meis protein from blood or cell samples in order to determine meis+ phenotype patients. The partner has to comply with EU "in vitro diagnostic medical device regulation 2017/746".
The company is looking for SMEs, R&D institutions and universities that can develop and manufacture meis protein detection assays in compliance with EU "in vitro diagnostic medical device regulation 2017/746".
The company has ongoing cooperations with researchers from France and Japan to develop and validate several other small molecules related to diabetes and solid tumours.